Smolarz K, Malke G, Voth E, Scheidhauer K, Eckel H E, Jungehülsing M, Schicha H
Department of Nuclear Medicine, University of Cologne, Germany.
Thyroid. 2000 May;10(5):425-9. doi: 10.1089/thy.2000.10.425.
Early detection of local and regional recurrence is the main goal during follow-up of patients with larynx and pharynx cancer. Hypothyroidism occurring in those patients stays frequently undiagnosed as screening for hypothyroidism is not part of the routine follow-up. This study was performed to assess the prevalence of hypothyroidism in these patients. We included 120 patients (106 male, 14 female) with larynx or pharynx cancer treated more than 2 months earlier (mean = 41 months) in the study. Cancer treatment consisted of either surgery (n = 44), radiotherapy (n = 15), or surgery combined with postoperative radiotherapy (n = 61). In all patients, thyroid function studies (thyrotropin [TSH], free triiodothyronine [FT3], and free thyroxine [FT4]) were performed. Twenty-six of all patients (22%) were hypothyroid; in two patients hypothyroidism was diagnosed postoperatively and these two patients were on replacement therapy with thyroid hormones. The highest rate of hypothyroidism (34%) was present in patients treated with surgery combined with radiotherapy, whereas among patients treated with surgery only 7% were hypothyroid (p < 0.001). There was no difference in the duration of follow-up between therapy and inclusion in the study between those two groups. Two of 15 patients treated only with radiotherapy were diagnosed hypothyroid, but in this group the latency was shorter (p < 0.05). The results indicate that thyroid function studies should be routinely performed in the follow-up of head and neck cancer patients, especially if radiotherapy was part of the treatment.
早期发现局部和区域复发是喉癌和咽癌患者随访期间的主要目标。这些患者中发生的甲状腺功能减退症常常未被诊断出来,因为甲状腺功能减退症筛查并非常规随访的一部分。本研究旨在评估这些患者中甲状腺功能减退症的患病率。我们纳入了120例(106例男性,14例女性)喉癌或咽癌患者,这些患者在2个多月前(平均41个月)接受了治疗。癌症治疗包括手术(n = 44)、放疗(n = 15)或手术联合术后放疗(n = 61)。对所有患者均进行了甲状腺功能检查(促甲状腺激素[TSH]、游离三碘甲状腺原氨酸[FT3]和游离甲状腺素[FT4])。所有患者中有26例(22%)患有甲状腺功能减退症;2例患者术后被诊断为甲状腺功能减退症,这2例患者正在接受甲状腺激素替代治疗。接受手术联合放疗的患者中甲状腺功能减退症的发生率最高(34%),而仅接受手术治疗的患者中7%患有甲状腺功能减退症(p < 0.001)。两组患者从治疗到纳入研究的随访时间没有差异。仅接受放疗的15例患者中有2例被诊断为甲状腺功能减退症,但该组的潜伏期较短(p < 0.05)。结果表明,对头颈部癌症患者进行随访时应常规进行甲状腺功能检查,尤其是在放疗作为治疗一部分的情况下。